Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) Director Matthew K. Fust sold 12,195 shares of the business’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the transaction, the director now owns 14,860 shares of the company’s stock, […]
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Buy" by Brokerages themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) had its price objective increased by research analysts at Needham & Company LLC from $36.00 to $40.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price points to a potential […]
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Buy" from Analysts themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Candriam S.C.A. lessened its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 18.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 49,480 shares of the biopharmaceutical company’s stock after selling 11,155 shares during the period. Candriam S.C.A. owned approximately 0.07% of Ultragenyx Pharmaceutical […]